Watson Names Mark Durand Chief Financi... ( CORONA Calif. Nov. 16 /- WatsonPh...)

Watson Names Mark Durand Chief Financial Officer

Date:11/16/2007

CORONA, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced the appointment of Mark W. Durand, 48, as Senior Vice President and Chief Financial Officer.

Mr. Durand brings to Watson more than 20 years of executive pharmaceutical experience in finance, operations, business development and marketing. As Senior Vice President and Chief Financial Officer for Watson, Mr. Durand will be responsible for all of the Company's financial operations and will play a principal role in Watson's corporate development activities. He will report directly to Paul Bisaro, Watson's President and Chief Executive Officer.

"We are excited to bring someone with Mark's experience to join the executive management team," said Paul Bisaro. "His extensive experience in both the generic and branded pharmaceutical industries and familiarity with our business model will complement the strength we have within our finance and corporate development groups as we continue to position Watson for future growth."

Mr. Durand joins Watson following his position as Chief Financial Officer and Senior Vice President Finance and Business Development for Teva Pharmaceuticals N.A., where he was responsible for all financial functions and business development activities related to Teva's North America operations, including licensing activities. He also played an integral role in the integration of Ivax Pharmaceuticals after it was acquired by Teva. Prior to his tenure at Teva, Mr. Durand held a number of positions of growing responsibility in the areas of finance, business development and marketing at Bristol-Myers Squibb. His financial roles there included Vic
'/>"/>

0

GOOD

Page: 1 2
Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
6. Mediware Names Thomas K. Mann Chief Executive Officer
7. Cleveland-based Health Care Tech Company Within3 Names New CEO
8. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
9. Patient Safety Authority Board of Directors Names Infection Advisory Panel
10. Hooper Holmes Names Chris Behling President of Health & Wellness Division
11. MDMA Names New Director of Federal Affairs

Post Your Comments:

Watson Names Mark Durand Chief Financi...( CORONA Calif. Nov. 16 /- WatsonPh...),Health